A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

计划入组 104 人 · 首次发布于 2025 年 10 月 10 日

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

计划入组 82 人 · 首次发布于 2024 年 10 月 8 日

Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema

计划入组 185 人 · 首次发布于 2023 年 6 月 9 日

Sanofi's SAR446597 Gene Therapy Receives FDA Fast Track Designation for Geographic Atrophy Treatment

Sanofi's SAR446523 Receives FDA Orphan Drug Designation for Relapsed/Refractory Multiple Myeloma

Innate Pharma Announces Advancement of Sanofi-Developed NK Cell Engager SAR443579/IPH6101 to Phase 2 for Blood Cancer Patients